BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 33408413)

  • 1. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice.
    Koblan LW; Erdos MR; Wilson C; Cabral WA; Levy JM; Xiong ZM; Tavarez UL; Davison LM; Gete YG; Mao X; Newby GA; Doherty SP; Narisu N; Sheng Q; Krilow C; Lin CY; Gordon LB; Cao K; Collins FS; Brown JD; Liu DR
    Nature; 2021 Jan; 589(7843):608-614. PubMed ID: 33408413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
    Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
    J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular Smooth Muscle-Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome.
    Hamczyk MR; Villa-Bellosta R; Gonzalo P; Andrés-Manzano MJ; Nogales P; Bentzon JF; López-Otín C; Andrés V
    Circulation; 2018 Jul; 138(3):266-282. PubMed ID: 29490993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient expression of an adenine base editor corrects the Hutchinson-Gilford progeria syndrome mutation and improves the skin phenotype in mice.
    Whisenant D; Lim K; Revêchon G; Yao H; Bergo MO; Machtel P; Kim JS; Eriksson M
    Nat Commun; 2022 Jun; 13(1):3068. PubMed ID: 35654881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.
    Strandgren C; Revêchon G; Sola-Carvajal A; Eriksson M
    Biochem Soc Trans; 2017 Dec; 45(6):1279-1293. PubMed ID: 29127216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Progerin Suppression and Lamin A Restoration Rescue Hutchinson-Gilford Progeria Syndrome.
    Sánchez-López A; Espinós-Estévez C; González-Gómez C; Gonzalo P; Andrés-Manzano MJ; Fanjul V; Riquelme-Borja R; Hamczyk MR; Macías Á; Del Campo L; Camafeita E; Vázquez J; Barkaway A; Rolas L; Nourshargh S; Dorado B; Benedicto I; Andrés V
    Circulation; 2021 Nov; 144(22):1777-1794. PubMed ID: 34694158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A conserved splicing mechanism of the LMNA gene controls premature aging.
    Lopez-Mejia IC; Vautrot V; De Toledo M; Behm-Ansmant I; Bourgeois CF; Navarro CL; Osorio FG; Freije JM; Stévenin J; De Sandre-Giovannoli A; Lopez-Otin C; Lévy N; Branlant C; Tazi J
    Hum Mol Genet; 2011 Dec; 20(23):4540-55. PubMed ID: 21875900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of a Hutchinson-Gilford progeria syndrome monkey model by base editing.
    Wang F; Zhang W; Yang Q; Kang Y; Fan Y; Wei J; Liu Z; Dai S; Li H; Li Z; Xu L; Chu C; Qu J; Si C; Ji W; Liu GH; Long C; Niu Y
    Protein Cell; 2020 Nov; 11(11):809-824. PubMed ID: 32729022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating the synthesis of progerin, the mutant prelamin A in Hutchinson-Gilford progeria syndrome, with antisense oligonucleotides.
    Fong LG; Vickers TA; Farber EA; Choi C; Yun UJ; Hu Y; Yang SH; Coffinier C; Lee R; Yin L; Davies BS; Andres DA; Spielmann HP; Bennett CF; Young SG
    Hum Mol Genet; 2009 Jul; 18(13):2462-71. PubMed ID: 19376814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
    Finley J
    Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear membrane ruptures underlie the vascular pathology in a mouse model of Hutchinson-Gilford progeria syndrome.
    Kim PH; Chen NY; Heizer PJ; Tu Y; Weston TA; Fong JL; Gill NK; Rowat AC; Young SG; Fong LG
    JCI Insight; 2021 Aug; 6(16):. PubMed ID: 34423791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
    Glynn MW; Glover TW
    Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermal fibroblasts in Hutchinson-Gilford progeria syndrome with the lamin A G608G mutation have dysmorphic nuclei and are hypersensitive to heat stress.
    Paradisi M; McClintock D; Boguslavsky RL; Pedicelli C; Worman HJ; Djabali K
    BMC Cell Biol; 2005 Jun; 6():27. PubMed ID: 15982412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of angiogenic incompetence in Hutchinson-Gilford progeria via downregulation of endothelial NOS.
    Gete YG; Koblan LW; Mao X; Trappio M; Mahadik B; Fisher JP; Liu DR; Cao K
    Aging Cell; 2021 Jul; 20(7):e13388. PubMed ID: 34086398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interruption of progerin-lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype.
    Lee SJ; Jung YS; Yoon MH; Kang SM; Oh AY; Lee JH; Jun SY; Woo TG; Chun HY; Kim SK; Chung KJ; Lee HY; Lee K; Jin G; Na MK; Ha NC; Bárcena C; Freije JM; López-Otín C; Song GY; Park BJ
    J Clin Invest; 2016 Oct; 126(10):3879-3893. PubMed ID: 27617860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eliminating the synthesis of mature lamin A reduces disease phenotypes in mice carrying a Hutchinson-Gilford progeria syndrome allele.
    Yang SH; Qiao X; Farber E; Chang SY; Fong LG; Young SG
    J Biol Chem; 2008 Mar; 283(11):7094-9. PubMed ID: 18178963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
    Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes.
    Moulson CL; Fong LG; Gardner JM; Farber EA; Go G; Passariello A; Grange DK; Young SG; Miner JH
    Hum Mutat; 2007 Sep; 28(9):882-9. PubMed ID: 17469202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells.
    Mehta IS; Eskiw CH; Arican HD; Kill IR; Bridger JM
    Genome Biol; 2011 Aug; 12(8):R74. PubMed ID: 21838864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose CRISPR-Cas9 therapy extends lifespan of mice with Hutchinson-Gilford progeria syndrome.
    Beyret E; Liao HK; Yamamoto M; Hernandez-Benitez R; Fu Y; Erikson G; Reddy P; Izpisua Belmonte JC
    Nat Med; 2019 Mar; 25(3):419-422. PubMed ID: 30778240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.